Hydroxyprogesterones
Hydroxyprogesterones are a family of progesterone derivatives in which a hydroxyl group is added at one or more positions on the progesterone molecule. Two members are clinically significant in reproductive medicine.
17-alpha-hydroxyprogesterone (17-OHP) is an endogenous intermediate in the steroidogenesis pathway. Elevated serum 17-OHP is the standard screening marker for non-classic congenital adrenal hyperplasia (CAH), particularly 21-hydroxylase deficiency, which can mimic PCOS in presentation. In RRM, clinicians include 17-OHP measurement in the androgen excess evaluation to exclude non-classic CAH before attributing hyperandrogenism to PCOS.
17-alpha-hydroxyprogesterone caproate (17-OHPC), formerly marketed as Makena, is a synthetic injectable progestin. The FDA withdrew its approval in 2023 after a confirmatory trial showed no significant reduction in preterm birth. Major obstetric societies no longer recommend its use. RRM's emphasis on bioidentical progesterone support distinguishes its approach from 17-OHPC-based protocols.
This content is for educational purposes only and does not constitute medical advice. Consult an RRM clinician or healthcare provider for guidance specific to your situation.